Order the NovaSeq X Series
Advanced chemistry, optics, and informatics combine to deliver exceptional speed and data quality, outstanding throughput and scalability.
This sequencing research panel assesses genes involved in characterisation of undifferentiated stem cells or their differentiated derivatives.
This panel enables gene expression analysis for stem cell research. It targets 930 gene expression markers to characterize human embryonic stem (hES) cell identity and assess phenotypic variations between embryonic stem cell isolates. The majority of the gene content (609 markers) in this panel comes directly from the work of the International Stem Cell Initiative consortium and characterization of human embryonic stem cell lines by this consortium.
AmpliSeq for Illumina Community Panels are made-to-order. We provide the designs for your convenience; however, they do not have associated performance metrics. For predesigned and tested content, view AmpliSeq for Illumina Ready-to-Use Panels.
AmpliSeq for Illumina Community Panels contain content selected and designed with input from leading disease researchers. You can order this community panel as is, or customize the panel to meet your needs, using DesignStudio software to add or remove genes and amplicons.
Input quantity | 1–100 ng; recommended 10 ng per pool |
---|---|
Method | Amplicon sequencing |
Nucleic acid type | RNA |
Number of amplicons | 930 total (1 pool) |
Species category | Human |
Technology | Sequencing |
In addition to the community panel, you will also need an AmpliSeq Library PLUS kit and index adapters.
AmpliSeq™ RNA Stem Cell Research Panel for Illumina®
20020496
Targeted custom amplicon panel optimized for specific targets or genomic content of interest. Library PLUS and index adapters sold separately.
List Price:
Discounts:
Showing of
Product
Qty
Unit Price
Product
Catalog ID
Quantity
Unit price
Reach out for information about our products and services, or get answers to questions about our technology.
Your email address is never shared with third parties.